新辅助化疗并未不成比例地影响晚期卵巢癌肥胖患者术后并发症发生率或化疗时间
该研究分析2010年1月至2015年7月间507例IIIC-IV期卵巢癌患者,其中肥胖115例(22.6%)。肥胖患者中初次肿瘤细胞减灭术与新辅助化疗后30天再入院率分别为30.2%与11.5%(p<0.02)。肥胖与术后感染、再入院/再手术及任何术后并发症相关,但肥胖与新辅助化疗对术后并发症无显著交互作用。
要点
- 肥胖患者中初次肿瘤细胞减灭术与新辅助化疗的30天再入院率分别为30.2%与11.5%(p<0.02)。
- 非肥胖患者中初次肿瘤细胞减灭术与新辅助化疗的任何术后并发症发生率分别为19.4%与28%(p=0.044)。
- 肥胖与新辅助化疗对术后并发症的交互作用在所有模型中均不显著。
核心结论
- 新辅助化疗的选择不应仅基于肥胖状态,因为肥胖患者术后并发症的减少与非肥胖患者相似。
研究设计与样本
- 研究收集2010年1月至2015年7月间治疗的IIIC-IV期卵巢癌患者数据,共507例,其中肥胖115例(22.6%),非肥胖392例(77.3%),肥胖定义为BMI≥30。
- 采用单因素/多因素逻辑回归分析,结局包括术后感染、再入院、任何术后并发症和化疗时间,并在模型中纳入交互项以判断新辅助化疗对术后并发症的影响是否受肥胖状态影响。
主要发现
- 肥胖患者中,初次肿瘤细胞减灭术与新辅助化疗的术后感染率分别为42.9%与30.8%(p=0.12),30天再入院率分别为30.2%与11.5%(p<0.02),任何术后并发症发生率分别为44.4%与30.8%(p=0.133)。
- 非肥胖患者中,初次肿瘤细胞减灭术与新辅助化疗的术后感染率分别为20.0%与12.9%(p=0.057),30天再入院率分别为16.9%与9.2%(p=0.02),任何术后并发症发生率分别为19.4%与28%(p=0.044)。
- 肥胖与术后感染相关(OR 2.3;95%CI 1.22-4.33),与30天再入院/再手术相关(OR 2.27;95%CI 1.08-3.21),与任何术后并发症发生相关(OR 2.1;95%CI 1.13-3.74)。
- 在所有预测术后并发症的模型中,肥胖与新辅助化疗之间均无显著交互作用。
临床怎么用
- 作者认为,新辅助化疗的选择不应仅基于肥胖状态,因为肥胖患者术后并发症的减少与非肥胖患者相似。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine whether neoadjuvant chemotherapy (NACT) disproportionately benefits obese patients. METHODS: Data were collected from stage IIIC-IV ovarian cancer patients treated between 01/2010-07/2015. We performed univariate/multivariate logistic regression analyses with post-operative infection, readmission, any postoperative complication, and time to chemotherapy as outcomes. An interaction term was included in models, to determine if the effect of NACT on post-operative complications was influenced by obesity status. RESULTS: Of 507 patients, 115 (22.6%) were obese and 392 (77.3%) were non-obese (obese defined as BMI ≥30). Among obese patients undergoing primary debulking surgery (PDS) vs. NACT, rates of postoperative infection were 42.9% vs. 30.8% (p = 0.12), 30-day readmission 30.2% vs. 11.5% (p < 0.02), and any post-operative complication were 44.4% vs 30.8% (p = 0.133). Among non-obese patients undergoing PDS vs. NACT, rates of post-operative infection were 20.0% vs. 12.9% (p = 0.057), 30-day readmission 16.9% vs. 9.2% (p = 0.02), and any post-operative complication were 19.4% vs 28% (p = 0.044). Obesity was associated with post-operative infection (OR 2.3; 95%CI 1.22-4.33), 30-day readmission/reoperation (OR 2.27; 95%CI 1.08-3.21) and the development of any post-operative complication (OR 2.1; CI 1.13-3.74). However, there was not a significant interaction between obesity and NACT in any of the models predicting post-operative complications. CONCLUSIONS: The decision to use NACT should not be predicated on obesity alone, as the reduction in post-operative complications in obese patients is similar to non-obese patients.
引用
- Kanbergs AN, Manning-Geist BL, Pelletier A, et al. Neoadjuvant chemotherapy does not disproportionately influence post-operative complication rates or time to chemotherapy in obese patients with advanced-stage ovarian cancer. Gynecol Oncol. 2020. PMID: 32951891. doi:10.1016/j.ygyno.2020.09.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。